The cell therapy biotech Capricor just released new Phase 3 data from its Duchenne Muscular Dystrophy (DMD) program The firm is trialing its stromal cell product deramiocel for DMD. These new results are very encouraging and stronger than past data. Why am I excited here? These newest deramiocel results released in a PR show statistically […]
The post Could Capricor’s report of strong data on deramiocel for Duchenne spark FDA approval? appeared first on The Niche.